Show simple item record

dc.contributor.authorVlaicu, S.I.
dc.contributor.authorTatomir, A.
dc.contributor.authorRus, V.
dc.date.accessioned2019-09-13T16:42:04Z
dc.date.available2019-09-13T16:42:04Z
dc.date.issued2019
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85067103364&doi=10.3389%2ffimmu.2019.01054&partnerID=40&md5=a9df677b10c3c95a2ed418a7c1ee8cde
dc.identifier.urihttp://hdl.handle.net/10713/10754
dc.description.abstractThe complement system represents an effective arsenal of innate immunity as well as an interface between innate and adaptive immunity. Activation of the complement system culminates with the assembly of the C5b-9 terminal complement complex on cell membranes, inducing target cell lysis. Translation of this sequence of events into a malignant setting has traditionally afforded C5b-9 a strict antitumoral role, in synergy with antibody-dependent tumor cytolysis. However, in recent decades, a plethora of evidence has revised this view, highlighting the tumor-promoting properties of C5b-9. Sublytic C5b-9 induces cell cycle progression by activating signal transduction pathways (e.g., Gi protein/ phosphatidylinositol 3-kinase (PI3K)/Akt kinase and Ras/Raf1/ERK1) and modulating the activation of cancer-related transcription factors, while shielding malignant cells from apoptosis. C5b-9 also induces Response Gene to Complement (RGC)-32, a gene that contributes to cell cycle regulation by activating the Akt and CDC2 kinases. RGC-32 is expressed by tumor cells and plays a dual role in cancer, functioning as either a tumor promoter by endorsing malignancy initiation, progression, invasion, metastasis, and angiogenesis, or as a tumor suppressor. In this review, we present recent data describing the versatile, multifaceted roles of C5b-9 and its effector, RGC-32, in cancer. Copyright Copyright 2019 Vlaicu, Tatomir, Rus and Rus.en_US
dc.description.sponsorshipThis work was supported in part by a Veterans Administration Merit Award I01BX001458 (to HR) and by an RO1 NS42011 grant (to HR).en_US
dc.description.urihttps://doi.org/10.3389/fimmu.2019.01054en_US
dc.language.isoen-USen_US
dc.publisherFrontiers Media S.A.en_US
dc.relation.ispartofFrontiers in Immunology
dc.subjectApoptosisen_US
dc.subjectC5b-9en_US
dc.subjectCanceren_US
dc.subjectCell proliferationen_US
dc.subjectRGC-32en_US
dc.titleRole of C5b-9 and RGC-32 in canceren_US
dc.typeArticleen_US
dc.identifier.doi10.3389/fimmu.2019.01054
dc.identifier.pmid31156630


This item appears in the following Collection(s)

Show simple item record